Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangyan Qiu

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2018
Targeting Tertiary Lymphoid Structures for Tumor ImmunotherapyHaidong Tang, Xiangyan Qiu, Casey Timmerman, et al.
Fish & Shellfish Immunology|May 3, 2024
Effects of replacing fishmeal with soybean meal on the immune and antioxidant capacity, and intestinal metabolic functions of red swamp crayfish Procambarus clarkiiMinglang Cai, Xiangyan Qiu, Huajun Zhang, et al.
Nature Communications|September 25, 2020
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockadeQi Peng, Xiangyan Qiu, Zihan Zhang, et al.
Clinical and Experimental Vaccine Research|November 11, 2024
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded studyRenan James Lim, Xiangyan Qiu, Edison Alberto, et al.
Clinical and Experimental Vaccine Research|November 11, 2024
Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trialRenan James Lim, Xiangyan Qiu, Robert Neil Leong, et al.
Nature Communications|November 4, 2018
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistanceYong Liang, Haidong Tang, Jingya Guo, et al.
The Journal of Clinical Investigation|January 17, 2018
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regressionHaidong Tang, Yong Liang, Robert A Anders, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2018
Targeting Tertiary Lymphoid Structures for Tumor ImmunotherapyHaidong Tang, Xiangyan Qiu, Casey Timmerman, et al.
Fish & Shellfish Immunology|May 3, 2024
Effects of replacing fishmeal with soybean meal on the immune and antioxidant capacity, and intestinal metabolic functions of red swamp crayfish Procambarus clarkiiMinglang Cai, Xiangyan Qiu, Huajun Zhang, et al.
Nature Communications|September 25, 2020
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockadeQi Peng, Xiangyan Qiu, Zihan Zhang, et al.
Clinical and Experimental Vaccine Research|November 11, 2024
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded studyRenan James Lim, Xiangyan Qiu, Edison Alberto, et al.
Clinical and Experimental Vaccine Research|November 11, 2024
Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trialRenan James Lim, Xiangyan Qiu, Robert Neil Leong, et al.
Nature Communications|November 4, 2018
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistanceYong Liang, Haidong Tang, Jingya Guo, et al.
The Journal of Clinical Investigation|January 17, 2018
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regressionHaidong Tang, Yong Liang, Robert A Anders, et al.
Pageof 1